Chronic rhinosinusitis with nasal polyps (CRSwNP)

Activity Release Date: August 14, 2020

Activity Expiration Date: August 13, 2021

1.0 hour activity | ACCME

Activity Overview
Nasal polyps impact 13 million Americans. In particular, nasal polyps affect 45% of people with adult-onset asthma and approximately 30% of people with chronic rhinosinusitis. This program reviews the latest evidence-based data on the role of biologics as therapy for chronic rhinosinusitis with nasal polyps.

Target Audience
This initiative is intended for otolaryngologists (ENTs) interested in better understanding the role of biologics in reducing inflammation and related symptomatology in ENT disorders, especially nasal polyposis.

Learning Objectives
Upon completion of the educational activity, participants should be able to:

• Describe the prevalence and underlying pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP)
• Review the emerging biologic targets and treatment options for chronic rhinosinusitis with nasal polyps (CRSwNP)
• Evaluate the clinical trial data on emerging therapeutics options for chronic rhinosinusitis with nasal polyps (CRSwNP) based on their mechanisms of action, efficacy, and safety data

Accreditation

CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare

Physicians
AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Criteria for Success
Statements of credit will be awarded based on the participant’s attendance, participation in the pre/post-test and submission of the activity evaluation form. A passing score of 70% on the quiz is required to receive credit. A certificate will be available upon successful completion of the quiz and evaluation. If you have questions about this CME activity, please contact AKH Inc. at [email protected]. There is no fee for this activity.

ABOUT OUR FACULTY

Stella E. Lee, MD
Assistant Professor of Otolaryngology—Head & Neck Surgery
University of Pittsburgh Medical Center
Pittsburgh, PA

Dr. Lee has disclosed the following relevant financial relationships: Consultant and Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Sanofi Regeneron Genzyme

AKH STAFF AND PLANNERS
Margaret V. Clark, MSc, RN, RRT – NPS, CMPP, Medical Writer/Interviewer: has no financial relationships to disclose.
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner: has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
Steve Eckert, AKH President & CEO, Planner: has no financial relationships to disclose.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure Declaration
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Required hardware/software:
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.

Copyright 2020 AKH Inc. No part of this publication may be produced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical photocopying, recording, or otherwise, without the prior permission of the publisher.